AC
GILD icon

Abbrea Capital’s Gilead Sciences GILD Stock Holding History

Abbrea Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,440
Closed -$202K – 233
2023
Q1 		$202K Buy
+2,440
New +$202K 0.03% 226
2020
Q2 		– Sell
-2,870
Closed -$215K – 188
2020
Q1 		$215K Buy
+2,870
New +$198K 0.06% 167
2018
Q2 		– Sell
-2,790
Closed -$210K – 171
2018
Q1 		$210K Buy
+2,790
New +$222K 0.07% 164
2017
Q4 		– Sell
-2,659
Closed -$215K – 157
2017
Q3 		$215K Buy
+2,659
New +$203K 0.08% 147

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Abbrea Capital's GILD Position: Q2 2023 in Review

Abbrea Capital sold out of Gilead Sciences (GILD) in Q2 2023, closing a stake of 2,440 shares — an estimated $202K sold.

Abbrea Capital first reported a position in GILD in Q3 2017 and held it in 4 quarters. The position peaked at $215K in Q1 2020. 1,701 funds tracked by Wall St. Rank hold GILD as of Q2 2023.

  • Abbrea Capital reported no remaining Gilead Sciences position as of Q2 2023 after selling out during the quarter.
  • Abbrea Capital sold 2,440 Gilead Sciences shares in Q2 2023, an estimated $202K.
  • Abbrea Capital first reported a position in Gilead Sciences in Q3 2017 and held it in 4 quarters.
  • Abbrea Capital's Gilead Sciences position peaked at $215K in Q1 2020.
  • 1,701 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2023.

Based on Abbrea Capital's 13F filing for Q2 2023, filed 1 Aug 2023.